The updated Phase 1 data are consistent with prior disclosures and reinforce cemsidomide's potential, but the stock may have already priced in these results given prior data releases. Watch for Phase 2 MOMENTUM trial enrollment updates and the educational webinar on June 18, 2026 for further catalysts. The combination trial with elranatamab could expand the addressable population if positive.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 11 $3.87entry
- T+1 · 5mo ago +0.78%α +0.23% · $3.90
- T+5 · 5mo ago +1.29%α +0.86% · $3.92
- T+20 · 4mo ago +10.85%α +8.96% · $4.29
- T+60 · 2mo ago −2.84%α −7.24% · $3.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
C4 Therapeutics presented updated Phase 1 data for cemsidomide at EHA 2026, showing a 53% overall response rate at the 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines). Responses deepened over time, with MRD negativity achieved in two patients. The data reinforce cemsidomide's differentiated safety profile and support its development as a potential best-in-class IKZF1/3 degrader, though the stock may have limited upside given prior data disclosures and the early-stage nature of the program.
Key Facts
- 53% ORR at 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines)
- 75% of patients received prior BCMA therapy and prior CAR-T or T-cell engager therapy
- Responses deepened over time: one patient at 100 µg deepened from PR to sCR, another from PR to VGPR
- MRD negativity achieved in two patients at 100 µg who achieved sCR and CR
- Median duration of response 7.9 months across all doses; 7 patients remain on treatment
- No discontinuations deemed related to cemsidomide; minimal dose reductions (5 patients, 7%)
- Phase 2 MOMENTUM trial (NCT07284758) is enrolling ~100 patients with ≥3 prior regimens
- Phase 1b combination trial with elranatamab (BCMAxCD3 bispecific) is ongoing
Financial Impact
No financial data provided; clinical-stage biotech with no approved products or revenue
Risk Factors
- Phase 2 MOMENTUM trial may not replicate Phase 1 ORR or durability
- Competition from other next-generation IKZF1/3 degraders and approved therapies
- Cemsidomide is investigational; regulatory approval is uncertain and years away
- Company has no approved products and relies on external financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310320 |
Track record
19 reports on CCCC
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers